[Pulmonary vascular interventions: innovating through adaptation and advancing through differentiation].

Pulmonary vascular intervention technology, with its minimally invasive and precise advantages, has been a groundbreaking advancement in the treatment of pulmonary vascular diseases. Techniques such as balloon pulmonary angioplasty (BPA), pulmonary artery stenting, and percutaneous pulmonary artery denervation (PADN) have significantly improved the prognoses for conditions such as chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary artery stenosis, and pulmonary arterial hypertension (PAH). Although based on coronary intervention (PCI) techniques such as guidewire manipulation and balloon dilatation, pulmonary vascular interventions require specific modifications to address the unique characteristics of the pulmonary circulation, low pressure, thin-walled vessels, and complex branching, to mitigate risks of perforation and thrombosis. Future directions include the development of dedicated instruments, multi-modality imaging guidance, artificial intelligence-assisted procedures, and molecular interventional therapies. These innovations aim to establish an independent theoretical framework for pulmonary vascular interventions, facilitating their transition from "adjuvant therapies" to "core treatments" in clinical practice.